14.11.2012 - Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
14 Nov 2012
14.11.2012 Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor "Dolutegravir", Disclosed by ViiV Healthcare
© Shionogi B.V. 2019. All rights reserved. This website is owned by Shionogi B.V. Registered with the Trade Register of the Dutch Chamber of Commerce under number 73229180. Registered address is Kingsfordweg 151, 1043GR, Amsterdam, the Netherlands.
Report Side Effect
Just to let you know, you are now moving to another website this is not under our control and Shionogi B.V. is not responsible for its contents.